2025-05-13T17:39:21-05:00 2024-12-31 390974031 WEGNER CPAS LLP 419 N LEE ST ALEXANDRIA VA 223142301 990 2024-01-01 821199380 GLOBAL COALITION FOR ADAPTIVE RESEARCH INC GLOB 4154948020 700 LARKSPUR LANDING CIRCLE 199 LARKSPUR CA 949391754 RACHAEL COLEMAN CFO/COO 4154948020 2025-05-13 1 0 GLENN MILLER CPA P00086726 7035190990 2025-05-07 2024 2025-03-06 01:10:19Z MEREDITH BUXTON 700 LARKSPUR LANDING CIRCLE 199 LARKSPUR CA 949391754 46057995 0 X GCARESEARCH.ORG X 2017 MD TO LEAD THE DEVELOPMENT AND ONGOING MANAGEMENT OF CLINICAL TRIAL PLATFORMS TO ACCELERATE THE DISCOVERY AND DEVELOPMENT OF TREATMENTS FOR PATIENTS WITH RARE AND DEADLY DISEASES. 8 5 39 5 0 0 3081228 1668304 23964880 24168345 1733052 1851839 0 0 28779160 27688488 1158000 16019 0 0 6144027 7624837 0 0 0 22408600 23254301 29710627 30895157 -931467 -3206669 59610730 63602270 19617460 24355112 39993270 39247158 X OUR MISSION IS TO LEAD THE DEVELOPMENT AND ONGOING MANAGEMENT OF CLINICAL TRIAL PLATFORMS TO ACCELERATE THE DISCOVERY AND DEVELOPMENT OF TREATMENTS FOR PATIENTS WITH RARE AND DEADLY DISEASES. 0 1 24705406 16019 21967531 GLIOBLASTOMA ADAPTIVE GLOBAL INNOVATIVE LEARNING ENVIRONMENT (GBM AGILE) IS GCAR'S FLAGSHIP AND MOST ADVANCED INITIATIVE - AN INTERNATIONAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL DESIGNED TO EVALUATE MULTIPLE INVESTIGATIONAL TREATMENTS FOR GLIOBLASTOMA OVER TIME, WITH THE GOAL OF IMPROVING PATIENT OUTCOMES. SINCE OPENING IN JULY 2019, GBM AGILE HAS SCREENED MORE THAN 2,250 PATIENTS AND CONTINUES TO ACTIVELY ENROLL PARTICIPANTS.IN 2024, KEY DATA AND UPDATES FROM GBM AGILE WERE SHARED WITH THE RESEARCH COMMUNITY THROUGH SEVERAL MAJOR CONFERENCES, INCLUDING THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO), SOCIETY FOR NEURO-ONCOLOGY (SNO), EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY (EANO), AND THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO).GCAR REMAINS COMMITTED TO SUPPORTING THE GLIOBLASTOMA RESEARCH AND CLINICAL COMMUNITY THROUGH ONGOING PHILANTHROPIC CONTRIBUTIONS TO ADVOCACY ORGANIZATIONS, AS WELL AS THROUGH EDUCATION, OUTREACH, AND ENGAGEMENT EFFORTS. IN 2024, PATIENT-CENTERED EDUCATIONAL PRESENTATIONS ON GBM AGILE WERE DELIVERED IN COLLABORATION WITH THE MUSELLA FOUNDATION FOR BRAIN TUMOR RESEARCH & INFORMATION AND AT THE GLIOBLASTOMA RESEARCH ORGANIZATION'S GLIOBLASTOMA SUMMIT IN MIAMI. 2095115 0 2200814 PROGRAMS IN DEVELOPMENT. ADDITIONAL EFFORTS ARE DEDICATED TO SUPPORTING THE LAUNCH, DESIGN, EDUCATION, OUTREACH, AND CLINICAL COMMUNITY ENGAGEMENT FOR MULTIPLE PROGRAMS CURRENTLY IN DEVELOPMENT, INCLUDING THOSE FOCUSED ON PANCREATIC CANCER, OVARIAN CANCER, AND PTSD. THESE ARE ALL RARE AND/OR LIFE-THREATENING CONDITIONS WITH AN URGENT NEED FOR INNOVATIVE TREATMENT OPTIONS.ONE SMALLER FEDERALLY FUNDED PROGRAM SUPPORTING COVID-19 RESEARCH CONCLUDED ITS WIND-DOWN PHASE AND OFFICIALLY ENDED IN JUNE 2024. 26800521 1 1 0 0 0 0 0 0 0 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 19 0 39 1 0 0 0 0 0 0 0 0 0 0 0 0 X 8 5 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X RACHAEL COLEMAN 4154948020 700 LARKSPUR LANDING CIRCLE STE 199 LARKSPUR CA 949391754 GARY GORDON MD PHD SENIOR MEDICAL ADVISOR AND DIRECTOR 16.00 X 165000 0 0 TIMOTHY CLOUGHESY MD CHIEF MEDICAL OFFICER AND DIRECTOR 16.00 X X 165000 0 0 WK ALFRED YUNG MD INVESTIGATOR INTERNATIONAL CHAIR & DIRECTOR 2.00 X 26628 0 0 SUJUAN BA PHD DIRECTOR 2.00 X 0 0 0 BRIAN ALEXANDER MD MPH DIRECTOR 2.00 X 0 0 0 FARAMARZ YOUSEFZADEH JD LLM CHAIRMAN OF THE BOARD 5.00 X 0 0 0 JOHN FRISHKOPF MMS DIRECTOR 2.00 X 0 0 0 WEBSTER CAVENEE PHD DIRECTOR 2.00 X 0 0 0 MATTHEW VIVA DIRECTOR, LEGAL/SECRETARY 40.00 X 255815 0 31047 MEREDITH BUXTON CHIEF EXECUTIVE OFFICER/PRESIDENT 40.00 X 932400 0 72129 RACHAEL COLEMAN CFO/COO/TREASURER 40.00 X 500489 0 35336 ASHLEY POWELL VICE PRESIDENT, TRIAL OPERATIONS 40.00 X 410000 0 46468 ROBERT MURRAY CHIEF BUSINESS AND STRATEGY OFFICER 40.00 X 529076 0 20833 RACHEL ROSENSTEIN SISSON SR DIR, COMMUNICATIONS/LEARNING AND DEVELOPMENT 40.00 X 196700 0 20273 SARAH UNTCH DIRECTOR, TRIAL OPERATIONS 40.00 X 239057 0 29559 TRACEY ROBERTS DIRECTOR, TRIAL OPERATIONS 40.00 X 246750 0 29676 HEATHER KLING SENIOR CLINICAL SCIENTIST 40.00 X 196577 0 18855 NAWEEN TAMJIDI SR. MGR,TRIAL OPERATIONS 40.00 X 193858 0 19100 4057350 0 323276 24 0 1 0 IQVIA 1700 PERIMETER PARK DR MORRISVILLE NC 27560 CRO SERVICES 15877603 MEDIDATA 350 HUDSON ST 9TH FLOOR NEW YORK NY 10014 DATA SERVICES 457758 BERRY CONSULTANTS LLC 3345 BEE CAVES RD STE 201 AUSTIN TX 78746 STATISTICAL CONSULTATION 260000 VOIANT 1171 S ROBERTSON BLVD PMB 414 LOS ANGELES CA 90035 CLINICAL RESEARCH 210634 4 1668304 1668304 TRIAL REVENUE 541700 24168345 24168345 24168345 1854131 1854131 18367215 18369507 -2292 -2292 -2292 27688488 24168345 0 1851839 X 16019 16019 3190221 2265885 924336 3620418 2597563 1022855 125860 89393 36467 336588 239065 97523 351750 249834 101916 44822 29253 15569 53804 53804 66764 66764 21197420 21195588 1832 8339 8339 45322 7203 38119 109948 11043 98905 12927 12927 295568 78633 216935 53947 3422 50525 141440 17620 123820 CREDIT LOSS 1224000 1224000 30895157 26800521 4094636 0 3206238 874264 1546512 3948737 1079637 702464 2040738 4705822 2848349 3555673 40029401 37399235 8859855 12416075 59610730 63602270 6428918 5722820 11938542 18132292 1250000 500000 19617460 24355112 X 39993270 39247158 39993270 39247158 59610730 63602270 -3206669 2460557 0 X 0 1 X 1 0 X 365772 504130 543271 3081228 1668304 6162705 365772 504130 543271 3081228 1668304 6162705 3523006 2639699 5866 5504 483944 1733052 1854131 4082497 10245202 136180649 0.25770 0.37100 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 MONEY MARKET FUNDS 12416075 F 12416075 REFUNDABLE ADVANCE 500000 500000 30126891 2460557 44610 -66764 2438403 27688488 0 27688488 30873003 44610 44610 30828393 66764 66764 30895157 PART XI, LINE 2D - OTHER ADJUSTMENTS: INVESTMENT FEES -66,764. 1 NATIONAL BRAIN TUMOR SOCIETY 55 CHAPEL STREET SUITE 006 NEWTON MA 02458 043068130 501(C)(3) 10000 0 GBM AWARENESS DAY AND WALK SPONSORSHIP 1 0 PART I, LINE 2: THE GRANTS WE ISSUED WERE UNRESTRICTED AND ARE INTENDED TO HELP SUPPORT THE RESPECTIVE ORGANIZATION'S MISSION. WE HAVE ASKED EACH ORGANIZATION TO KEEP ALL RECORDS OF THE USE OF THE GIFT IN THE NORMAL COURSE AND PROVIDE COPIES UPON REQUEST. X X 0 0 0 0 0 0 0 0 0 MEREDITH BUXTON CHIEF EXECUTIVE OFFICER/PRESIDENT 581800 0 350000 0 600 0 23550 0 48579 0 1004529 0 0 0 ROBERT MURRAY CHIEF BUSINESS AND STRATEGY OFFICER 359076 0 170000 0 0 0 19633 0 1200 0 549909 0 0 0 RACHAEL COLEMAN CFO/COO/TREASURER 349999 0 150000 0 490 0 19633 0 15703 0 535825 0 0 0 ASHLEY POWELL VICE PRESIDENT, TRIAL OPERATIONS 285000 0 125000 0 0 0 16400 0 30068 0 456468 0 0 0 MATTHEW VIVA DIRECTOR, LEGAL/SECRETARY 201672 0 53681 0 462 0 10744 0 20303 0 286862 0 0 0 TRACEY ROBERTS DIRECTOR, TRIAL OPERATIONS 210000 0 36750 0 0 0 9870 0 19806 0 276426 0 0 0 SARAH UNTCH DIRECTOR, TRIAL OPERATIONS 201507 0 37450 0 100 0 10058 0 19501 0 268616 0 0 0 RACHEL ROSENSTEIN SISSON SR DIR, COMMUNICATIONS/LEARNING AND 166950 0 29216 0 534 0 7855 0 12418 0 216973 0 0 0 HEATHER KLING SENIOR CLINICAL SCIENTIST 166827 0 29750 0 0 0 7707 0 11148 0 215432 0 0 0 NAWEEN TAMJIDI SR. MGR,TRIAL OPERATIONS 164983 0 28875 0 0 0 5463 0 13637 0 212958 0 0 0 GARY GORDON MD PHD SENIOR MEDICAL ADVISOR AND DIRECTOR 165000 0 0 0 0 0 0 0 0 0 165000 0 0 0 TIMOTHY CLOUGHESY MD CHIEF MEDICAL OFFICER AND DIRECTOR 165000 0 0 0 0 0 0 0 0 0 165000 0 0 0 FORM 990, PART III, LINE 3 ACTIV-4, A SMALL FEDERALLY FUNDED PROGRAM SUPPORTING COVID-19 RESEARCH CONCLUDED ITS WIND-DOWN PHASE AND OFFICIALLY ENDED IN JUNE 2024 FORM 990, PART VI, SECTION B, LINE 11B CFO WILL REVIEW WITH ACCOUNTING FIRM. ONCE NEAR FINAL WILL REVIEW WITH CEO. WHEN FORM IS FINAL, FORM IS REVIEWED WITH THE ENTIRE BOARD. FORM 990, PART VI, SECTION B, LINE 12C EACH DIRECTOR AND OFFICER IS REQUIRED TO SUBMIT AN UPDATED CONFLICT OF INTEREST STATEMENT ON AN ANNUAL BASIS. TO THE EXTENT THAT RELATIONSHIPS ARE IDENTIFIED VIA THESE STATEMENTS AND OTHER INFORMATION, THE INDIVIDUAL'S CONSTITUENT RECORD IN THE COMPANY DATABASE IS UPDATED TO INCLUDE THIS INFORMATION, FACILITATING PERIODIC QUERIES, AS NECESSARY. ANY BOARD MEMBER WITH A CONFLICT MUST IDENTIFY THE CONFLICT AT ANY BOARD MEETING WHERE THE CONFLICT IS RELEVANT. THE MEMBER CANNOT BE PRESENT AT ANY PART OF THE MEETING WHERE THE RELEVANT TOPIC IS DISCUSSED OR VOTED ON. THE MEMBER CANNOT BE COUNTED FOR A QUORUM. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION COMMITTEE AND BOARD OF DIRECTORS ARE RESPONSIBLE FOR THE REVIEW AND APPROVAL OF TOP LEVEL EXECUTIVE MANAGEMENT COMPENSATION ANNUALLY. INDEPENDENT PROFESSIONAL EXPERTS ARE CALLED UPON FOR HIGHER LEVEL POSITIONS AND ASSIST IN ESTABLISHING EXECUTIVE SALARIES IN THE COMPETITIVE MARKETPLACE. SALARIES IN BOTH FOR PROFIT AND NOT FOR PROFIT ORGANIZATIONS ARE EVALUATED WITH THE INTENT ON ENSURING THAT THE EXECUTIVE COMPENSATION PROGRAM FALLS WITHIN A REASONABLE RANGE OF COMPETITIVE PRACTICES FOR COMPARABLE POSITIONS AMONG SIMILARLY SITUATED ORGANIZATIONS. THE REVIEW INCLUDES INCENTIVE PLANS AND ALL FRINGE BENEFITS AS WELL AS BASE SALARY ARRANGEMENTS. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART IX, LINE 11G TRIAL EXPENSES: PROGRAM SERVICE EXPENSES 21,195,588. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 21,195,588. 401K MANAGEMENT: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 1,832. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,832.